{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:03:57Z","timestamp":1792789437939,"version":"4.5.0"},"reference-count":111,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione per l\u2019Oncologia Pediatrica (FOP)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Repurposing approved non-antitumor drugs is a promising and affordable strategy in drug discovery to identify new therapeutic uses different from the original medical indication that may help increase the number of possible, effective anticancer drugs. The use of drugs in ways other than their original FDA-approved indications could offer novel avenues such as bypassing the chemoresistance and recurrence seen with conventional therapy and treatment; moreover, it can offer a safe and economic strategy for combination therapy. Recent works have demonstrated the anticancer properties of the FDA-approved drug Mebendazole. This synthetic benzimidazole proved effective against a broad spectrum of intestinal Helminthiasis. Mebendazole can penetrate the blood\u2013brain barrier and has been shown to inhibit the malignant progression of glioma by targeting signaling pathways related to cell proliferation, apoptosis, or invasion\/migration, or by increasing the sensitivity of glioma cells to conventional chemotherapy or radiotherapy. Moreover, several preclinical models and ongoing clinical trials explore the efficacy of Mebendazole in multiple cancers, including acute myeloid leukemia, brain cancer, oropharyngeal squamous cell carcinoma, breast cancer, gastrointestinal cancer, lung carcinoma, adrenocortical carcinoma, prostate cancer, and head and neck cancer. The present review summarizes central literature regarding the anticancer effects of MBZ in cancer cell lines, animal tumor models, and clinical trials to suggest possible strategies for safe and economical combinations of anticancer therapies in brain cancer. Mebendazole might be an excellent candidate for the treatment of brain tumors because of its efficacy both when used as monotherapy and in combination as an enhancement to standard chemotherapeutics and radiotherapy, due to its effectiveness on tumor angiogenesis inhibition, cell cycle arrest, apoptosis induction, and targeting of critical pathways involved in cancer such as Hedgehog signaling. Therefore, attention to MBZ repurposing has recently increased because of its potential therapeutic versatility and significant clinical implications, such as reducing medical care costs and optimizing existing therapies. Using new treatments is essential, particularly when current therapeutics for patients with brain cancer fail.<\/jats:p>","DOI":"10.3390\/ijms24021334","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T01:33:12Z","timestamp":1673400792000},"page":"1334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers"],"prefix":"10.3390","volume":"24","author":[{"given":"Daniela","family":"Meco","sequence":"first","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-8765","authenticated-orcid":false,"given":"Giorgio","family":"Attin\u00e0","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mastrangelo","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Dipartimento Scienze della Salute della Donna, del Bambino e di Sanit\u00e0 Pubblica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[{"name":"Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Universit\u00e0 Cattolica del Sacro Cuore-Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3511","authenticated-orcid":false,"given":"Antonio","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Dipartimento Scienze della Salute della Donna, del Bambino e di Sanit\u00e0 Pubblica, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"9","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_2","unstructured":"World Health Organization (WHO) (2020, December 11). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000\u20132019, Available online: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin. Trials."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1039\/C5MB00306G","article-title":"Protein localization vector propagation: A method for improving the accuracy of drug repositioning","volume":"11","author":"Yeu","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1503\/cmaj.082041","article-title":"Rapidly rising clinical trial costs worry researchers","volume":"180","author":"Collier","year":"2009","journal-title":"CMAJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds","volume":"21","author":"Wurth","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/0929867327666200831141337","article-title":"Perspectives on Drug Repurposing","volume":"28","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ddstr.2011.06.008","article-title":"Repositioned drugs: Integrating intellectual property and regulatory strategies","volume":"8","author":"Smith","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology--patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1015531","DOI":"10.3389\/fgene.2022.1015531","article-title":"Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies","volume":"13","author":"Munj","year":"2022","journal-title":"Front. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.18632\/oncoscience.173","article-title":"Challenges and perspective of drug repurposing strategies in early phase clinical trials","volume":"2","author":"Kato","year":"2015","journal-title":"Oncoscience"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: Teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4155\/ppa.15.45","article-title":"The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis","volume":"5","author":"Bloom","year":"2016","journal-title":"Pharm. Pat. Anal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1089\/adt.2015.29015.beddrrr","article-title":"Creating new economic incentives for repurposing generic drugs for unsolved diseases using social finance","volume":"13","author":"Bloom","year":"2015","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fphar.2019.01664","article-title":"On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients","volume":"10","author":"Verbaanderd","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3347\/kjp.2021.59.3.189","article-title":"Albendazole and Mebendazole as Antiparasitic and Anticancer Agents: An Update","volume":"59","author":"Chai","year":"2021","journal-title":"Korean J. Parasitol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guerini, A.E., Triggiani, L., Maddalo, M., Bon\u00f9, M.L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., and Pasinetti, N. (2019). Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 11.","DOI":"10.3390\/cancers11091284"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4110\/in.2020.20.e29","article-title":"The antitumor potentials of benzimidazole anthelmintics as repurposing drugs","volume":"20","author":"Son","year":"2020","journal-title":"Immun. Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2016). World Health Organization Classification of Tumours of the Central Nervous System.","DOI":"10.1007\/s00401-016-1545-1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"2","author":"Louis","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild-type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1750-3639.2008.00129.x","article-title":"Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402","volume":"18","author":"Giannini","year":"2008","journal-title":"Brain Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1200\/JCO.2011.34.8086","article-title":"Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial","volume":"29","author":"Ducray","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bpa.12171","article-title":"International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading","volume":"24","author":"Louis","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neo.2015.02.002","article-title":"The challenges and the promise of molecular targeted therapy in malignant gliomas","volume":"17","author":"Wang","year":"2015","journal-title":"Neoplasia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1593\/neo.10688","article-title":"Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance","volume":"12","author":"Hatanpa","year":"2010","journal-title":"Neoplasia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/03009734.2012.665097","article-title":"PDGF and PDGF receptors in glioma","volume":"117","author":"Nazarenko","year":"2012","journal-title":"Upsala J. Med Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tilak, M., Holborn, J., New, L.A., Lalonde, J., and Jones, N. (2021). Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int. J. Mol. Sci., 12.","DOI":"10.3390\/ijms22041831"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/nen.0b013e31815f65fb","article-title":"Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers","volume":"67","author":"Yip","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1073\/pnas.87.21.8602","article-title":"Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas","volume":"87","author":"Sugawa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/07357907.2011.630050","article-title":"Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets","volume":"30","author":"Mao","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2015.1.FOCUS14755","article-title":"A practical review of prognostic correlations of molecular biomarkers in glioblastoma","volume":"38","author":"Karsy","year":"2015","journal-title":"Neurosurg. Focus."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrc2818","article-title":"Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma","volume":"10","author":"Huse","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3567","article-title":"Molecular mechanisms underlying RB protein function","volume":"14","author":"Dick","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1971.03190030039008","article-title":"Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1278 subjects","volume":"217","author":"Brugmans","year":"1971","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2125.1985.tb02616.x","article-title":"The pharmacokinetics and bioavailability of a tracer dose of (3H)-mebendazole in man","volume":"19","author":"Dawson","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00542095","article-title":"Chemotherapy of alveolar echinococcosis; comparison of plasma Mebendazole concentrations in animals and man","volume":"20","author":"Witassek","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","first-page":"M12","article-title":"Mebendazole","volume":"Volume 2","author":"Dollery","year":"1999","journal-title":"Therapeutic Drugs"},{"key":"ref_50","unstructured":"EMEA-European Medicines Evaluation Agency (1999). Mebendazole Summary Report by CVMP, EMEA. EMEA\/MRL\/625\/99-Final."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198815020-00001","article-title":"Clinical pharmacokinetics of anthelmintic drugs","volume":"15","author":"Edwards","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40262-015-0243-9","article-title":"A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole","volume":"54","author":"Pawluk","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop."},{"key":"ref_54","first-page":"142","article-title":"Repurposing of anthelminthics as anticancer drugs","volume":"2","author":"Hamilton","year":"2017","journal-title":"Oncomedicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00542462","article-title":"Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease","volume":"22","author":"Braithwaite","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-009-0683-y","article-title":"Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and Mebendazole: An interaction study in healthy volunteers","volume":"65","author":"Corti","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2125.1987.tb03186.x","article-title":"Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts","volume":"24","author":"Bekhti","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF00613522","article-title":"Treatment of hydatid disease with high oral doses of Mebendazole","volume":"31","author":"Luder","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00436-012-2954-2","article-title":"Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus","volume":"111","author":"Liu","year":"2012","journal-title":"Parasitol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/46.3.451","article-title":"Benzimidazoles in the treatment of alveolar echinococcosis: A comparative study and review of theliterature","volume":"46","author":"Reuter","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","first-page":"285","article-title":"Flubendazole andmebendazole in the treatment of trichuriasis and other helminthiases","volume":"4","author":"Yangco","year":"1981","journal-title":"Clin. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jcpt.13033","article-title":"Hepatotoxicity caused by Mebendazole in a patient with Gilbert\u2019s syndrome","volume":"44","author":"Tolomeo","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40268-016-0142-z","article-title":"Safety of mebendazole use during lactation: A case series report","volume":"16","author":"Karra","year":"2016","journal-title":"Drugs R D"},{"key":"ref_65","first-page":"769","article-title":"Anthelmintics. A comparative review of their clinical pharmacology","volume":"53","author":"Guyatt","year":"1997","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1183\/09031936.93.06020253","article-title":"Treatment of hydatid disease in childhood with Mebendazole","volume":"6","author":"Toppare","year":"1993","journal-title":"Eur. Respir. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2105\/AJPH.93.3.489","article-title":"Outbreak of Stevens-Johnson syndrome\/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan","volume":"93","author":"Chen","year":"2003","journal-title":"Am. J. Public Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jsps.2021.04.004","article-title":"Anthelmintics for drug repurposing: Opportunities and challenges","volume":"29","author":"Alavi","year":"2021","journal-title":"Saudi Pharm. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/DDDT.S65561","article-title":"Enhanced bioavailability and anthelmintic efficacy of Mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose","volume":"18","author":"Torrado","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00558451","article-title":"Plasma concentrations of Mebendazole during treatment of echinococcosis","volume":"17","author":"Karlaganis","year":"1980","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000238506","article-title":"Experimental chemotherapy and toxicity in mice of three Mebendazole polymorphic forms","volume":"33","author":"Guzman","year":"1987","journal-title":"Chemotherapy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0939-6411(03)00004-3","article-title":"Quality evaluation of generic drugs by dissolution test: Changing the USP dissolution medium to distinguish between active and non-active Mebendazole polymorphs","volume":"55","author":"Swanepoel","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_73","first-page":"712","article-title":"Efficacy of single-dose Mebendazole, polymorphic forms A and C, in the treatment of hookworm and Trichuris infections","volume":"24","author":"Charoenlarp","year":"1993","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","article-title":"Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model","volume":"21","author":"Bai","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_75","first-page":"651","article-title":"New drugs are not enough drug repositioning in oncology: An update","volume":"56","author":"Armando","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"118189","DOI":"10.1016\/j.lfs.2020.118189","article-title":"Drug repurposing andrelabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects","volume":"1","author":"Nath","year":"2020","journal-title":"Life Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/ERC-19-0341","article-title":"Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer","volume":"27","author":"Williamson","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1038\/s41598-021-88433-y","article-title":"A phase 2a clinical study on the safety and efficacy of individualized dosed Mebendazole in patients with advanced gastrointestinal cancer","volume":"26","author":"Mansoori","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Choi, H.S., Ko, Y.S., Jin, H., Kang, K.M., Ha, I.B., Jeong, H., Song, H.N., Kim, H.J., and Jeong, B.K. (2021). Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro. Molecules, 24.","DOI":"10.3390\/molecules26175118"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41416-019-0681-5","article-title":"Repurposing screen identifies Mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment","volume":"122","author":"Rushworth","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.18632\/oncotarget.28014","article-title":"Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer","volume":"6","author":"Williamson","year":"2021","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2020.10.010","article-title":"Potential and mechanism of Mebendazole for treatment and maintenance of ovarian cancer","volume":"160","author":"Elayapillai","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"120536","DOI":"10.1016\/j.lfs.2022.120536","article-title":"Mebendazole; from an antiparasitic drug to a promising candidate for drug repurposing in colorectal cancer","volume":"15","author":"Hegazy","year":"2022","journal-title":"Life Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00432-021-03698-0","article-title":"Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death","volume":"147","author":"Petersen","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_85","first-page":"12576","article-title":"The repurposed anthelmintic Mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma","volume":"21","author":"Dakshanamurthy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.18632\/oncotarget.14673","article-title":"Anthelmintic mebendazole enhances cisplatin\u2019s effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)","volume":"21","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Freisleben, F., Modemann, F., Muschhammer, J., Stamm, H., Brauneck, F., Krispien, A., Bokemeyer, C., Kirschner, K.N., Wellbrock, J., and Fiedler, W. (2021). Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910670"},{"key":"ref_88","first-page":"1264","article-title":"Effect of the antiparasitic drug Menbendaziole on cholangiocarcinoma growth","volume":"45","author":"Sawanyawisuth","year":"2014","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nor077","article-title":"Antiparasitic Mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme","volume":"13","author":"Bai","year":"2011","journal-title":"Neuro-Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41401-021-00752-y","article-title":"Author Correction: Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle","volume":"15","author":"Ren","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2119\/molmed.2017.00011","article-title":"Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors","volume":"23","author":"Gamble","year":"2017","journal-title":"Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jm300576q","article-title":"Predicting new indications for approved drugs using a proteochemometric method","volume":"55","author":"Dakshanamurthy","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with Mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the Hedgehog signaling pathway in cancer: A comprehensive review","volume":"20","author":"Skoda","year":"2018","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-14-0755-T","article-title":"Repurposing the antihelmintic Mebendazole as a hedgehog inhibitor","volume":"14","author":"Larsen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"N15","DOI":"10.1227\/01.neu.0000460594.93803.cb","article-title":"Repurposing mebendazole for the treatment of medulloblastoma","volume":"76","author":"Bodhinayake","year":"2015","journal-title":"Neurosurgery"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11060-018-03009-7","article-title":"Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma","volume":"140","author":"Skibinski","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.2147\/OTT.S143096","article-title":"Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism","volume":"24","author":"Markowitz","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10637-017-0503-7","article-title":"Vinblastine and antihelmintic Mebendazole potentiate temozolomide in resistant gliomas","volume":"36","author":"Kipper","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/1878-0261.12810","article-title":"In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor","volume":"14","author":"Carrasco","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1535-7163.MCT-06-0711","article-title":"MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival","volume":"6","author":"Demuth","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/gm293","article-title":"Gene expression and network-based analysis reveals a novel role for has-miR-9 and drug control over the p38 network in glioblastoma multiforme progression","volume":"3","author":"Efroni","year":"2011","journal-title":"Genome Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4158\/EP10390.CR","article-title":"Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma","volume":"17","author":"Dobrosotskaya","year":"2011","journal-title":"Endocr. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","article-title":"Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer","volume":"53","author":"Nygren","year":"2014","journal-title":"Acta Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1388-2457(03)00282-7","article-title":"A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas","volume":"115","author":"Trisciuzzi","year":"2004","journal-title":"Clin. Neurophysiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-015-2913-6","article-title":"The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: Real or not?","volume":"77","author":"Ruggiero","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1023900802254","article-title":"Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma","volume":"63","author":"Walker","year":"2003","journal-title":"J. Neurooncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1177\/0300060518765324","article-title":"Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment","volume":"46","author":"Ruggiero","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11060-011-0565-x","article-title":"Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review","volume":"104","author":"Henriksson","year":"2011","journal-title":"J. Neurooncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:45Z","timestamp":1760119545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":111,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021334"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021334","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}